BioLine Rx(BLRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BLRX BioLine Rx

Market Closed 12-20 16:00:00 EST

0.2030

+0.0010

+0.50%

盘后0.2084

+0.0054+2.66%

19:50 EST

High0.2080	Low0.1970	Vol921.55K
Open0.2050	D1 Closing0.2020	Amplitude5.45%
Mkt Cap16.24M	Tradable Cap14.79M	Total Shares79.99M
T/O187.83K	T/O Rate1.26%	Tradable Shares72.88M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"BLRX","market":"US","secType":"STK","nameCN":"BioLine Rx","latestPrice":0.203,"timestamp":1734728400000,"preClose":0.202,"halted":0,"volume":921549,"hourTrading":{"tag":"盘后","latestPrice":0.2084,"preClose":0.203,"latestTime":"19:50 EST","volume":716,"amount":149.4872,"timestamp":1734742250701},"delay":0,"floatShares":72876739,"shares":79990660,"eps":-0.261915,"marketStatus":"Market Closed","change":0.001,"latestTime":"12-20 16:00:00 EST","open":0.205,"high":0.208,"low":0.197,"amount":187828.596624,"amplitude":0.054455,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.261915,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1734944400000},"marketStatusCode":7,"adr":0,"adrRate":15,"exchange":"NASDAQ","adjPreClose":0.202,"preHourTrading":{"tag":"盘前","latestPrice":0.205,"preClose":0.202,"latestTime":"09:27 EST","volume":85807,"amount":17676.996244,"timestamp":1734704836404},"postHourTrading":{"tag":"盘后","latestPrice":0.2084,"preClose":0.203,"latestTime":"19:50 EST","volume":716,"amount":149.4872,"timestamp":1734742250701},"volumeRatio":0.845597282997786,"impliedVol":0.7969,"impliedVolPercentile":0.6349},"requestUrl":"/m/hq/s/BLRX","defaultTab":"news","newsList":[{"id":"2490533013","title":"Press Release: Silexion Therapeutics Appoints Renowned Cancer Therapeutics Expert Prof. Amnon Peled to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2490533013","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490533013?lang=en_us&edition=fundamental","pubTime":"2024-12-10 21:30","pubTimestamp":1733837400,"startTime":"0","endTime":"0","summary":"Prof. Peled, a globally recognized scientific authority who has been involved in multiple successful publicly traded bio-pharma companies, will assist Silexion as it advances its RNAi platform and next-generation therapies targeting KRAS mutations. Ilan Hadar, Chairman and CEO of Silexion, commented: \"We are thrilled to welcome Prof. Peled to our Board of Directors. His unparalleled expertise in cancer biology, stem cell mobilization, and therapeutic development will be invaluable as Silexion continues to advance its pipeline of RNAi-based therapies for difficult-to-treat cancers. Prof. Peled's track record in translating innovative science into impactful clinical outcomes aligns perfectly with our mission to address unmet needs in oncology.\". Prof. Peled serves as the Director of the Gene Therapy Institute at Hadassah Medical Center in Jerusalem, where his research focuses on cytokine roles in hematopoietic stem cell biology, inflammation, and cancer. Over his 28-year career, he has l","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","NQmain","PHH","BK4555","BK4139","BK4099","MNQmain","03160","QID","TQQQ","SLXN","LENZ",".IXIC","QLD","TM","BK4585","BLRX","PSQ","SQQQ","WRD"],"gpt_icon":1},{"id":"2488971924","title":"BLRX: Ayrmid Assumes Commercialization Efforts","url":"https://stock-news.laohu8.com/highlight/detail?id=2488971924","media":"Zacks Small Cap Research","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488971924?lang=en_us&edition=fundamental","pubTime":"2024-12-04 00:11","pubTimestamp":1733242260,"startTime":"0","endTime":"0","summary":"A few days prior to its third quarter earnings report, BioLineRx Ltd.  announced a commercialization agreement with Ayrmid Ltd. and its subsidiary Gamida Cell Ltd. BioLineRx will grant Ayrmid rights to commercialize Aphexda  across all indications except in solid tumors and in all territories except Asia. The arrangement will provide a $10 million upfront payment to BioLineRx, royalties ranging from 18% to 23% and the potential for $87 million in commercial milestones. After a transition period, BioLineRx’ expenses are expected to decline by about 70% as the company reverts to a research and development firm.The announcement of the arrangement with Ayrmid was followed by the third quarter earnings report where total revenues reached $4.9 million and net loss was  million. Aphexda revenues were down sequentially to $1.7 million and lower than expected expenses across the board, especially sales and marketing led to the less severe-than-expected loss which was about 60% of what we had fo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/blrx-ayrmid-assumes-commercialization-efforts-161100452.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4567","LU2430703178.SGD","LU1599440770.SGD","BK4581","IE00BGHQF631.EUR","IE00BGHQF748.EUR","IE00BVYPNV92.GBP","LU0980610538.SGD","LU2264538146.SGD","BLRX","BK4588","LU0742537680.HKD","BK4533","LU0772969993.USD","LU1481011671.HKD","IE00B3PB1722.GBP","IE00B42XCP33.USD","LU1064131342.USD","LU1291159041.SGD","BK4504","LU1988902786.USD","BK4109","BLK","LU2430703095.HKD","LU2430703251.USD","IE00BDGV0183.EUR","LU1670628061.USD","LU2463526074.USD","IE00BVYPNW00.USD","LU0208291251.USD","ASH","BK4135","LU0648001328.SGD","BK4585","LU1481011911.USD","LU0731783394.SGD","IE00B64PRP62.GBP","BK4534","BK4139","LU1201861249.SGD","LU1989771016.USD","LU0731783048.USD","IE00B3QW5Z07.USD","LU0130102774.USD","BK4535","LU0320765489.SGD","LU2505996681.GBP","LU0070302665.USD","LU1280957306.USD","LU1074936037.SGD"],"gpt_icon":0},{"id":"2486884156","title":"JonesTrading Reaffirms Their Buy Rating on Bioline RX Ltd Sponsored ADR (BLRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2486884156","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486884156?lang=en_us&edition=fundamental","pubTime":"2024-11-27 01:45","pubTimestamp":1732643109,"startTime":"0","endTime":"0","summary":"JonesTrading analyst Justin Walsh reiterated a Buy rating on Bioline RX Ltd Sponsored ADR (BLRX – Research Report) today. The company’s shares open...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jonestrading-reaffirms-their-buy-rating-on-bioline-rx-ltd-sponsored-adr-blrx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jonestrading-reaffirms-their-buy-rating-on-bioline-rx-ltd-sponsored-adr-blrx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BLRX"],"gpt_icon":0},{"id":"2486002772","title":"BioLine Rx Ltd (BLRX) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic Shifts","url":"https://stock-news.laohu8.com/highlight/detail?id=2486002772","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486002772?lang=en_us&edition=fundamental","pubTime":"2024-11-26 23:00","pubTimestamp":1732633235,"startTime":"0","endTime":"0","summary":"Total Revenue: $4.9 million for Q3 2024, compared to no revenue in Q3 2023.Cost of Revenue: $0.8 million for Q3 2024, with no cost recorded in Q3 2023.Research and Development Expenses: $2.6 million for Q3 2024, down from $2.7 million in Q3 2023.Sales and Marketing Expenses: $5.5 million for Q3 2024, down from $8.1 million in Q3 2023.General and Administrative Expenses: $1.4 million for Q3 2024, slightly down from $1.5 million in Q3 2023.Net Loss: $5.8 million for Q3 2024, compared to $16 million in Q3 2023.Cash, Cash Equivalents, and Short-term Bank Deposits: $29.2 million as of September 30, 2024.Market Share of APHEXDA: Achieved 10% market share of total CXCR4 inhibitor usage in the US by end of Q3 2024.GuruFocus has detected 5 Warning Signs with BLRX.BioLine Rx Ltd  executed a significant licensing agreement with Ayrmid Ltd., providing a $10 million upfront payment and potential commercial milestones of $87 million.APHEXDA, BioLine Rx Ltd 's stem cell mobilization agent, achieved a","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/N0d66K5qtIENnAyTSH3qgg--~B/aD0yMjt3PTIxNTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/us.finance.gurufocus/d79d11a91f6f8286cb526f81c4e041bd","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/N0d66K5qtIENnAyTSH3qgg--~B/aD0yMjt3PTIxNTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/us.finance.gurufocus/d79d11a91f6f8286cb526f81c4e041bd"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bioline-rx-ltd-blrx-q3-150035812.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BLRX"],"gpt_icon":0},{"id":"2486309120","title":"BioLine RX Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2486309120","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486309120?lang=en_us&edition=fundamental","pubTime":"2024-11-26 01:23","pubTimestamp":1732555380,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BLRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 25, 2024 12:23 ET (17:23 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLRX"],"gpt_icon":0},{"id":"2486672030","title":"BioLineRx price target lowered to $9 from $21 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2486672030","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486672030?lang=en_us&edition=fundamental","pubTime":"2024-11-26 01:00","pubTimestamp":1732554007,"startTime":"0","endTime":"0","summary":"H.C. Wainwright lowered the firm’s price target on BioLineRx (BLRX) to $9 from $21 and keeps a Buy rating on the shares after the company announced...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biolinerx-price-target-lowered-to-9-from-21-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biolinerx-price-target-lowered-to-9-from-21-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BLRX"],"gpt_icon":0},{"id":"2486085141","title":"BioLineRx Secures Key Deals to Boost Shareholder Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2486085141","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486085141?lang=en_us&edition=fundamental","pubTime":"2024-11-25 20:31","pubTimestamp":1732537904,"startTime":"0","endTime":"0","summary":"Bioline RX Ltd Sponsored ADR (BLRX) has released an update. BioLineRx Ltd has entered a strategic license agreement with Ayrmid Ltd. for its APHEXD...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/biolinerx-secures-key-deals-to-boost-shareholder-value?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/biolinerx-secures-key-deals-to-boost-shareholder-value?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BLRX"],"gpt_icon":0},{"id":"2486853083","title":"BioLineRx GAAP EPS of $0.00 beats by $0.07, revenue of $4.94M misses by $0.35M","url":"https://stock-news.laohu8.com/highlight/detail?id=2486853083","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486853083?lang=en_us&edition=fundamental","pubTime":"2024-11-25 20:04","pubTimestamp":1732536257,"startTime":"0","endTime":"0","summary":"BioLineRx press release : Q3 GAAP EPS of $0.00  beats by $0.07. Revenue of $4.94M  misses by $0.35M. As of September 30, 2024, the company had cash, cash equivalents, and short-term bank deposits of $29.2 million. Following the out-license to Ayrmid, the equity investment from Highbridge and the debt repayment to Blackrock, the Company's cash, cash equivalents and short-term bank deposits are expected to be approximately $20 million, which management believes will be sufficient to fund operations into 2026, as currently planned","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4329101-biolinerx-gaap-eps-of-000-beats-by-007-revenue-of-494m-misses-by-035m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["BLRX"],"gpt_icon":0},{"id":"2486088608","title":"BioLine Rx Q3 2024 GAAP EPS $(0.00) Beats $(0.05) Estimate, Sales $4.94M Miss $5.29M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2486088608","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486088608?lang=en_us&edition=fundamental","pubTime":"2024-11-25 20:02","pubTimestamp":1732536157,"startTime":"0","endTime":"0","summary":"BioLine Rx (NASDAQ:BLRX) reported quarterly losses of $(0.00) per share which beat the analyst consensus estimate of $(0.05) by 98 percent.  The company reported quarterly sales of $4.94 million which missed the analyst","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/42160146/bioline-rx-q3-2024-gaap-eps-0-00-beats-0-05-estimate-sales-4-94m-miss-5-29m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"BioLine Rx Q3 2024 GAAP EPS $(0.00) Beats $(0.05) Estimate, Sales $4.94M Miss $5.29M Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLRX"],"gpt_icon":0},{"id":"2486608861","title":"Press Release: BioLineRx Reports Third Quarter 2024 Financial Results and Provides Update on Transformation to Drive Shareholder Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2486608861","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486608861?lang=en_us&edition=fundamental","pubTime":"2024-11-25 20:00","pubTimestamp":1732536000,"startTime":"0","endTime":"0","summary":"BioLineRx Reports Third Quarter 2024 Financial Results and Provides Update on Transformation to Drive Shareholder Value. - Executed license agreement with Ayrmid Ltd. for APHEXDA  for $10 million upfront, up to $87 million in commercial milestones, and 18-23% tiered royalties on sales -. - Entered into agreement to reduce and restructure long-term debt by $16.5 million -. - Annual operational expenses expected to decline by over 70% following out-license of APHEXDA  commercial program to Ayrmid -. - Company to continue to support motixafortide PDAC program while evaluating additional assets for development in rare diseases and oncology -. \"Looking forward, our streamlined and nimble company has a new financial foundation supported by sales royalties and potential milestone payments, which will allow our experienced team to develop important new therapies in rare disease and oncology that address areas with high unmet need. We will also focus on advancing our motixafortide PDAC program ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","BK4139","R","BLRX","ASH","BK4232","BK4109","SCD","LU2463526074.USD"],"gpt_icon":0},{"id":"2486704418","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2486704418","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486704418?lang=en_us&edition=fundamental","pubTime":"2024-11-25 19:00","pubTimestamp":1732532400,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Bath & Body Wrks                                3Q       .47       BMO. ·Central Gdn & Pet                               4Q      (.22)      AMC. ·Zoom Video Comm.                                  3Q      1.31   4:05 PM. ·Abercrombie & Fitch                              3Q      2.39   7:30 AM. ·Analog Devices Inc.                              4Q      1.64   7:00 AM. ·Best Buy Co. Inc.                                3Q      1.30       BMO. ·H World Grp Ltd                                 3Q       .60       AMC","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["A","LESL","BLRX","DDD","FRO","ZS","ARWR","PNST","CRDO","ZM","BBWI","SJM","URBN","TITN","NJR","MDWD","CENTA","VBNK","BBY","EMBC","ENTA","CDLR","HPQ","DKS","PDCO","PNNT","CMP","AMBA","ADSK","PFLT","HTHT","AMWD","ADI","CENT","MIMI","MNSO","WWD","OGI","DELL","BLBD","YY","VFS","NAT","NTNX","WDAY","ANF","JWN","HAFN"],"gpt_icon":1},{"id":"2485937732","title":"BioLineRx Q3 2024 Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2485937732","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485937732?lang=en_us&edition=fundamental","pubTime":"2024-11-23 00:19","pubTimestamp":1732292389,"startTime":"0","endTime":"0","summary":"BioLineRx  is scheduled to announce Q3 earnings results on Monday, November 25th, before market open.The consensus EPS Estimate is -$0.11and the consensus Revenue Estimate is $5.29M.Over the last 2 years, BLRX has beaten EPS estimates 25% of the time and has beaten revenue estimates 25% of the time.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4322193-biolinerx-q3-2024-earnings-preview","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["BLRX"],"gpt_icon":0},{"id":"2485268401","title":"BioLine RX Ltd  expected to post a loss of 5 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2485268401","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485268401?lang=en_us&edition=fundamental","pubTime":"2024-11-22 21:32","pubTimestamp":1732282353,"startTime":"0","endTime":"0","summary":"BioLine RX Ltd  expected to post a loss of5cents a share - Earnings Preview BioLine RX Ltd BLRX.OQ, BLRX.O is expected to show a rise in quarterly revenue when it reports  results on November 25 for t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241122:nL8N3MT14P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLRX"],"gpt_icon":0},{"id":"2485825131","title":"BioLineRx, Ayrmid enter license agreement for motixafortide through Gamida Cell","url":"https://stock-news.laohu8.com/highlight/detail?id=2485825131","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485825131?lang=en_us&edition=fundamental","pubTime":"2024-11-22 19:35","pubTimestamp":1732275326,"startTime":"0","endTime":"0","summary":"Unlock your investing potential with TipRanks Premium - Now At 40% OFF!Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter. Bioline RX Ltd Sponsored ADR  Q3 Earnings Cheat Sheet. BioLineRx’s Motixafortide Shows Promise in Sickle Cell","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/c8pJ6Hc13EFaByQh6DEJ0A--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/0176eac0ccabb4c894de3218c38cf5eb","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/c8pJ6Hc13EFaByQh6DEJ0A--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/0176eac0ccabb4c894de3218c38cf5eb"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/biolinerx-ayrmid-enter-license-agreement-113526432.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biolinerx-ayrmid-enter-license-agreement-113526432.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","GMDA","BLRX"],"gpt_icon":0},{"id":"2485496506","title":"BioLineRx inks licensing deal, share purchase agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2485496506","media":"seekingalpha","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485496506?lang=en_us&edition=fundamental","pubTime":"2024-11-21 21:00","pubTimestamp":1732194010,"startTime":"0","endTime":"0","summary":"Daniel GrizeljBioLineRx (NASDAQ:BLRX) ARDs fell ~19% in the premarket Thursday after the Israeli biotech announced a share purchase agreement in conjunction with a licensing deal with U.K.-based Ayrmi","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1126636461/image_1126636461.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1126636461/image_1126636461.jpg?io=getty-c-w750"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4316271-biolinerx-stock-sinks-share-purchase-deal","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["BK4139","BLRX","TQQQ","QLD","PSQ","MNQmain","GMDAQ","QID","NQmain","SQQQ",".IXIC"],"gpt_icon":1},{"id":"2485460742","title":"BiolineRx Ltd. Announces New Direct Offering of Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2485460742","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485460742?lang=en_us&edition=fundamental","pubTime":"2024-11-21 20:17","pubTimestamp":1732191447,"startTime":"0","endTime":"0","summary":"Bioline RX Ltd Sponsored ADR (BLRX) has released an update. BiolineRx Ltd., an Israeli company, has announced a registered direct offering involvin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/biolinerx-ltd-announces-new-direct-offering-of-shares?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/biolinerx-ltd-announces-new-direct-offering-of-shares?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BLRX"],"gpt_icon":0},{"id":"2485546452","title":"BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.","url":"https://stock-news.laohu8.com/highlight/detail?id=2485546452","media":"PR Newswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485546452?lang=en_us&edition=fundamental","pubTime":"2024-11-21 19:30","pubTimestamp":1732188600,"startTime":"0","endTime":"0","summary":"– BioLineRx to receive $10 million upfront payment from Ayrmid Ltd.  plus up to $87 million in commercial milestones, as well as royalties on net sales ranging from 18% to 23% –。– BioLineRx retains rights to develop and commercialize motixafortide in solid tumors, including PDAC –。–BioLineRx received $9 million equity investment from certain funds managed by Highbridge Capital Management, LLC to support company's pipeline and expansion –。– Transactions enable significant reduction in BioLineRx's operational expenses and debt, and allow the company to focus on development activities in areas of high unmet need in oncology and rare diseases –。Under the terms of the agreement, BioLineRx granted Ayrmid an exclusive license to develop and commercialize APHEXDA  across all indications, excluding solid tumor indications, and in all territories other than Asia. BioLineRx previously granted an exclusive license agreement to Gloria Biosciences for APHEXDA  in the Asia region.BioLineRx also enter","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Ah_tWEJOaQ25Wfnu5DpEFw--~B/aD0xMDc7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/4bb57788683b16dda8d726d9c8d1ac35","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Ah_tWEJOaQ25Wfnu5DpEFw--~B/aD0xMDc7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/4bb57788683b16dda8d726d9c8d1ac35"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/biolinerx-ayrmid-ltd-enter-exclusive-113000874.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biolinerx-ayrmid-ltd-enter-exclusive-113000874.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BLRX"],"gpt_icon":1},{"id":"2484190852","title":"BioLineRx to Report Third Quarter 2024 Results on November 25, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2484190852","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484190852?lang=en_us&edition=fundamental","pubTime":"2024-11-20 20:19","pubTimestamp":1732105140,"startTime":"0","endTime":"0","summary":"Management to Hold Conference Call at 8:30 a.m. EST. TEL AVIV, Israel, Nov. 20, 2024 /PRNewswire/ -- BioLineRx Ltd.  , a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its unaudited financial results for the third quarter ended September 30, 2024 on Monday, November 25, 2024, before the U.S. markets open.The Company will host a conference call at 8:30 a.m. EST featuring remarks by Philip Serlin, Chief Executive Officer.To access the conference call, please dial +1-888-281-1167 from the U.S. or +972-3-918-0685 internationally. A live webcast and a replay of the call can be accessed through the event pageon the Company's website. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast. The call replay will be available approximately two hours after completion of the live conference call. A dial-in replay of the call will ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/kyl_J9QACBdXE2SRRv_59Q--~B/aD0xMDc7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/b069ac9f15d655849a2707e7c3811a1a","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/kyl_J9QACBdXE2SRRv_59Q--~B/aD0xMDc7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/b069ac9f15d655849a2707e7c3811a1a"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/biolinerx-report-third-quarter-2024-121900229.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biolinerx-report-third-quarter-2024-121900229.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BLRX"],"gpt_icon":1},{"id":"2484910403","title":"BioLine RX Ltd  expected to post a loss of 5 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2484910403","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484910403?lang=en_us&edition=fundamental","pubTime":"2024-11-19 20:02","pubTimestamp":1732017777,"startTime":"0","endTime":"0","summary":"BioLine RX Ltd  expected to post a loss of5cents a share - Earnings Preview BioLine RX Ltd BLRX.OQ, BLRX.O is expected to show a rise in quarterly revenue when it reports  results on November 21 (esti","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241119:nL8N3MQ10I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLRX"],"gpt_icon":0},{"id":"2483488077","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2483488077","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483488077?lang=en_us&edition=fundamental","pubTime":"2024-11-13 19:00","pubTimestamp":1731495600,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BRFS","CINT","ADAP","ENLT","GOEV","KMDA","BZH","GLOB","HBM","UGP","INO","ICAD","AMAT","DTI","INKT","DFLI","SHCO","KRMD","GAMB","EXAI","CREX","CELC","LVLU","SLE","IVVD","MIST","ASND","MCRB","BEEM","BN","DMAC","CPRT","KORE","HAYN","SLRN","DGII","JD","AFCG","INVZ","LQDA","MURA","CIG","HI","SONO","BLRX","BOXL","EC","DNMR","BRAG"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.biolinerx.com","stockEarnings":[{"period":"1week","weight":-0.0974},{"period":"1month","weight":-0.6277},{"period":"3month","weight":-0.6938},{"period":"6month","weight":-0.6559},{"period":"1year","weight":-0.8777},{"period":"ytd","weight":-0.8707}],"compareEarnings":[{"period":"1week","weight":-0.0216},{"period":"1month","weight":0.0011},{"period":"3month","weight":0.0403},{"period":"6month","weight":0.0857},{"period":"1year","weight":0.2506},{"period":"ytd","weight":0.2437}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.","yearOnYearQuotes":[{"month":1,"riseRate":0.692308,"avgChangeRate":0.118845},{"month":2,"riseRate":0.461538,"avgChangeRate":-0.042962},{"month":3,"riseRate":0.230769,"avgChangeRate":-0.095051},{"month":4,"riseRate":0.307692,"avgChangeRate":-0.047194},{"month":5,"riseRate":0.538462,"avgChangeRate":0.061857},{"month":6,"riseRate":0.384615,"avgChangeRate":-0.023898},{"month":7,"riseRate":0.538462,"avgChangeRate":0.03754},{"month":8,"riseRate":0.357143,"avgChangeRate":-0.055743},{"month":9,"riseRate":0.428571,"avgChangeRate":-0.016762},{"month":10,"riseRate":0.357143,"avgChangeRate":-0.013928},{"month":11,"riseRate":0.285714,"avgChangeRate":-0.057325},{"month":12,"riseRate":0.357143,"avgChangeRate":-0.063171}],"exchange":"NASDAQ","name":"BioLine Rx","nameEN":"BioLine Rx"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BioLine Rx(BLRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest BioLine Rx(BLRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"BioLine Rx,BLRX,BioLine Rx股票,BioLine Rx股票老虎,BioLine Rx股票老虎国际,BioLine Rx行情,BioLine Rx股票行情,BioLine Rx股价,BioLine Rx股市,BioLine Rx股票价格,BioLine Rx股票交易,BioLine Rx股票购买,BioLine Rx股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BioLine Rx(BLRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest BioLine Rx(BLRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction